glp 1 with dpp 4 PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: DPP4 Mechanisms underlying GLP-1, GIP, and
Description
In this patient, semaglutide was restarted directly at 2 mg subcutaneously once weekly, the maximum approved dose for type 2 diabetes, without adherence to the recommended titration schedule
Reproductive Biomedicine Online, 59 (2), 255267

This review covers the development of multi-agonist therapies, including GLP-1glucagon and GIPGLP-1glucagon receptor agonists, which represent a significant advancement in obesity treatment

Using multiple GLP-1 medications simultaneously is generally not recommended due to overlapping mechanisms and compounded side effect risk

This realization set the stage for two parallel strategies that unfolded in the 1990s and 2000s: (1) development of injectable GLP-1 analogues resistant to degradation, and (2) development of DPP-4 inhibitors to protect and elevate native GLP-1 levels ( [44] )

Complications From Gastroparesis/Stomach Paralysis The National Institute of Diabetes and Digestive and Kidney Diseases lists a range of complications that can arise from gastroparesis: Dehydration from repeated vomiting Malnutrition stemming from poor nutrient absorption Difficulty controlling blood sugar (blood glucose) levels Low-calorie intake Decreased quality of life Bezoars (solid mass of food in the stomach, preventing digestion), which can cause: Blockage Ulcers Bleeding If a bezoar keeps food from moving to the small intestine, gastroparesis can be life-threatening
